News

Neuvivo Launches to Develop Effective Treatments for ALS

Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases based on the University of California, San Francisco lab discoveries by co-founder Michael McGrath, today announced its corporate launch, the expansion of its executive team, and the creation...

Exai Bio Launches Big in Series A Financing

Exai Bio, a next-generation liquid biopsy company based on the University of California, San Francisco’s technologies for early cancer detection developed in Dr.

Neurona Therapeutics to Present New Data for Lead Neural Cell Therapy Program

Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology. A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been...

The Truth About Innovation

OTMA Executive Director Anthony Francis opens up about MedTech innovation and using the academic institution as a launchpad for startups. MORE

Chroma Medicine Launches with $125M

Chroma Medicine, a NewCo based on UCSF technologies to advance programmable epigenetic editors that harness innate mechanisms to precisely control gene ex

Neurona Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy in Epilepsy Patients

Neurona Therapeutics, a biotherapeutics company founded in UCSF technology to advance restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has received clearance of its Investigational New Drug (IND) application f

Strategic Alliances Head, Peter Kotsonis, Named Assistant Vice Chancellor

After a process that involved extensive HR input from all 10 UC campuses, plus an extensive internal review within UCSF, Peter Kotsonis has been promoted to “Assistant Vice Chancellor of Business Development, Innovation, and Partnerships”.

Pliant Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial

Pliant Therapeutics, a clinical-stage biotechnology company founded by UCSF researchers Bill Degrado and Dean Sheppard, with a focus on discovering and developing novel therapeutics for the treatment of fibrosis, today announced positive interim results from a Phase 2a positron emission tomography...

Hani Goodarzi Awarded Prestigious Vilcek Prize

Catalyst Awardee 

And the winners are...

SAN FRANCISCO, October 12, 2021 - UCSF Health Hub and UCSF Health Hub Awards committee is proud to announce the 20 winning companies and Hall of Fame inductees for the 2021 UCSF Health Awards. The winning UCSF companies include: Best of UCSF DNA - Companies with Product: Genentech Best of UCSF...